Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)

Published bySiw Bråten Modified over 5 years ago

Similar presentations

Presentation on theme: "Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)"— Presentation transcript:

1 Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. A, Sequential fluorescence imaging of the MDA-MB-468 tumor-bearing MHC-dKO NOG mouse after Cy5.5-labeled BsAb intravenous injection from 24 hours to 28 days. B, Fluorescence imaging of the NCI-H2170 tumor-bearing MHC-dKO NOG mouse at 24 hours after the BsAb injection. C, Fluorescence imaging in the resected organs, including the MDA-MB-468 tumor on day 28 after Cy5.5-labeled BsAb injection (200 μg/body). D, Serum BsAb concentration after a 100 μg injection into 5 BALB/cA mice. Blood was sequentially collected for 2 minutes to 48 hours after the injection to measure serum BsAb concentration. Each point represents the mean ± SD of 5 mice (i.v., intravenous injection). Akira Iizuka et al. Clin Cancer Res 2019;25: ©2019 by American Association for Cancer Research

Download ppt "Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)"

Similar presentations

H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.

Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.
C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.
Vaccine MN confer protective innate and adaptive immunity.

Vaccine MN confer protective innate and adaptive immunity.
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys. Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys.

Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys. Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys.
Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.

Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.
Effect of HA on hematopoietic recovery in tumor-bearing mice.

Effect of HA on hematopoietic recovery in tumor-bearing mice.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
In vivo homing of intravenously injected CSNRDARRC peptide to bladder tumor in rats. In vivo homing of intravenously injected CSNRDARRC peptide to bladder.

In vivo homing of intravenously injected CSNRDARRC peptide to bladder tumor in rats. In vivo homing of intravenously injected CSNRDARRC peptide to bladder.
(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.
Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.

In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.
Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Similar presentations

Ads by Google